News from intercell ag A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 10, 2011, 02:53 ET Intercell AG Announces Q1 2011 Results and Updates on R&D Progress

Today, the biotech-vaccine company Intercell AG (VSE: ICLL) announced its financial results for Q1 and presented an update on the Company's...


May 05, 2011, 02:53 ET Intercell Announces New Management Structure

Today Intercell AG (VSE: ICLL) announced that the company's Supervisory Board has appointed Thomas Lingelbach as new Chief Executive Officer (CEO)...


Apr 11, 2011, 02:32 ET Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Intercell AG (VSE: ICLL) today announced that following a pre-specified...


Apr 01, 2011, 02:18 ET Intercell Announces Next Steps of Development for Pseudomonas Vaccine

Today Intercell AG (VSE: ICLL) announced that it has agreed with Novartis to advance Intercell's investigational Pseudomonas aeruginosa vaccine into...


Mar 01, 2011, 02:35 ET Intercell Announces Q4 and Preliminary Full Year 2010 Financial Results

Today Intercell AG (VSE: ICLL) announced its financial results for Q4 and the preliminary results for the full financial year 2010 and presented an...


Feb 23, 2011, 03:05 ET Intercell Completes Placement of EUR 33.0m Senior Convertible Debt Financing

Intercell AG (Vienna Stock Exchange, ICLL) ("Intercell" or the "Company") today announced that it successfully placed EUR 33.0m of Senior Unsecured...


Feb 22, 2011, 01:00 ET Intercell Starts Offering of EUR 30.8m Senior Convertible Debt Financing

Intercell AG (VSE: ICLL) today announced the offering of EUR 30.8m of Senior Unsecured Convertible Notes (the "Notes"). The Notes will be placed in a ...


Dec 12, 2010, 06:00 ET Intercell Provides Update On Clinical Trials For The Patch-Based Travelers' Diarrhea Vaccine

Travelers' Diarrhea vaccine candidate failed to meet efficacy endpoints to protect against enterotoxigenic E. coli (ETEC) (defined as cases in which...


Nov 09, 2010, 02:51 ET Intercell AG Announces Q3 2010 Results and Updates on R&D Progress and Management

Today, Intercell AG (VSE: ICLL) announced its financial results for the third quarter of 2010 and presented an update on the Company's key R&D...


Oct 25, 2010, 02:47 ET Intercell Reports Positive Results From Its Phase II Pseudomonas Aeruginosa Investigational Vaccine Study for Certain Hospital-Acquired Infections

Intercell AG (VSE: ICLL) today announced results from a Phase II clinical trial involving the company's investigational nosocomial vaccine candidate...


Oct 21, 2010, 02:38 ET Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C

Intercell AG (VSE; "ICLL") and Romark Laboratories L.C. today announced plans to commence clinical trials of Intercell's investigational therapeutic...


Sep 30, 2010, 12:31 ET Intercell AG Appoints Staph Leavenworth Bakali as Chief Business Officer

Intercell AG (VSE: ICLL) today announced that effective October 1, 2010, Staph Leavenworth Bakali will join its Management Board as Chief Business...


Aug 17, 2010, 02:40 ET Intercell Announces Q2 and H1 2010 Financial Results and Updates on Program Progress

Today, Intercell AG (VSE: ICLL) announced its financial results for Q2 and H1 2010. IXIARO®/JESPECT® sales increased significantly from EUR 2.4m in...


May 11, 2010, 02:53 ET Intercell AG Announces Q1 2010 Results and Updates on R&D Progress

Today, the biotech-vaccine company Intercell AG (VSE: ICLL) announced its financial results for Q1 and presented an update on the Company's...


May 06, 2010, 02:27 ET Intercell Acquires Antibody Technology Platform to Further Exploit Its Capabilities to Combat Infectious Diseases

Intercell AG (VSE: ICLL) today announced that it has signed an agreement with Cytos Biotechnology Ltd. to acquire Cytos' platform technology for...


Apr 22, 2010, 07:00 ET Intercell Programs and Expertise Highlighted at World Vaccine Congress

Intercell AG (VSE; "ICLL") today announced that members of the management team presented at the World Vaccine Congress on innovation, the company's...


Mar 02, 2010, 04:22 ET Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results

Today, the biotech-vaccine company Intercell AG (Pink Sheets: INRLY) (VSE: ICLL) announced its financial results for Q4 and the preliminary results...